Alpha pharma
ActiveSummary
Alpha pharma has been active since 2014 and the Belgian State Gazette contains no insolvency or warning signals. The 2024 annual accounts show equity of €569,000 and a net result of €114,414. Equity is growing by ~12.4% per year across the filed fiscal years. Its solvency ranks better than 58% of 9620 sector peers (fiscal year 2024). The computed 12-month bankruptcy probability is 0.8% (low).
Checked score
Score 2024
Axes · tick = 2023
Profitability80▼-3
Solvency71▲+8
Growth78=
Track record100
Bankruptcy probability, 12 months
0.8%
Low
0%0.5%1.5%4%10%≥ 25%
Credit up to €40,000 at 30 days acceptable
Liquidity tight (current ratio 1.21 against 0.98 in 2023; short-term debt: 36.3% and cash: 14% of total assets), and 54.4% of the assets are financed with debt.
Credit check for your own amount and term
Open the credit simulator : see how the verdict changes with amount, term and advance.
Signals
Three signals. The signal on the left, the evidence on the right.
−lowers risk+raises risk○neutral
raises risk · Higher-failure-rate sector
In this sector companies fail more often than the Belgian average.
Gazette · bankruptcies per sector, NACE 47
Relative position
BE, all sectors
reference
Retail trade (NACE 47)
about 45% more bankruptcies
← fewer bankruptcies
more bankruptcies →
lowers risk · Long track record
A company with a long track record statistically fails less often than a young one.
KBO · incorporation dateAge against the risk zone
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2024 was due by 31-07-2025 and was filed on 18-07-2025, 13 days ahead of the deadline.
NBB · 10 filingsDeviation from the deadline
2025
not confirmed
2024
13 d early
2023
8 d late
2022
39 d early
2021
31 d late
2020
26 d late
2019
73 d late
← before the deadline
after the deadline →
tick = median of all Belgian filingsring = median in the sector
This company filed its last 6 accounts on average 14 days after the deadline; the sector median for financial year 2024 is on the deadline day, and 46% of the sector filed late.
Checked, nothing found (1)
History
Go further with this company
How much credit can you give this customer, and on what term?Credit simulator What should you check before you do business with this company?Supplier due diligence Can you accept this company as a client under the anti-money-laundering law?AML client file Which of your other customers can you e-invoice via Peppol?Peppol check How does this company compare with its sector?Sector benchmark What changed in the latest annual accounts?What changed
Is this your company? See how customers and banks see it.
Investigating this company? Keep it with today's facts in a case file.
Financials · fiscal year 2024, abbreviated schema
Equity
€569,000▲ 25.2%
2023 · €454,586
Total assets
€1.2m▲ 4.2%
2023 · €1.2m
Net result
€114,414▼ 17.6%
2023 · €138,773
Working capital
€95,684
2023 · -€9,429
Trend over the years
Click a name to add, emphasise or remove a line.
Every figure with its change against the fiscal year before
favourable
unfavourable
Line20202021202220232024
Operating result€131,318▲ 29.9%€234,936▲ 78.9%€197,829▼ 15.8%€190,367▼ 3.8%€160,951▼ 15.5%
Net result€81,984▲ 27.3%€170,760▲ 108%€120,457▼ 29.5%€138,773▲ 15.2%€114,414▼ 17.6%
Equity€401,713▲ 25.6%€572,473▲ 42.5%€315,813▼ 44.8%€454,586▲ 43.9%€569,000▲ 25.2%
Total assets€1.4m▲ 2.5%€1.4m▲ 1.7%€1.2m▼ 11.7%€1.2m▼ 3.9%€1.2m▲ 4.2%
Debt€986,656▼ 4.6%€839,948▼ 14.9%€931,473▲ 10.9%€743,711▼ 20.2%€679,645▼ 8.6%
Working capital€69,643▲ 833%€105,885▲ 52.0%-€170,432-€9,429▲ 94.5%€95,684
Staff (FTE)0.9▲ 80.0%0.9=1.1▲ 22.2%1.9▲ 72.7%1.6▼ 15.8%
Turnover and EBIT margin not published: the abbreviated schema does not require them.
Result per fiscal year
Operating resultNet result
The operating result has fallen three years in a row; 2024 is 15% below 2023.
Balance-sheet composition
2024 in colour, 2023 as the grey bar beneath
Assets €1.2m
Fixed assets
€700,176 ▼ 5.4%
Current assets
€548,468 ▲ 19.7%
Equity and liabilities €1.2m
Equity
€569,000 ▲ 25.2%
Debt
€679,645 ▼ 8.6%
Debt's share of the balance-sheet total falls from 62.1% to 54.4%. Equity is higher and debt is lower.
Key figures and ratios
EBITDA
€211,135▼
2023 · €268,546
Cash flow
€164,598▼
2023 · €216,952
Current ratio
1.21▲
2023 · 0.98
Quick ratio
0.75▲
2023 · 0.60
Debt to equity
1.19▼
2023 · 1.64
ROE
20.1%▼
2023 · 30.5%
ROA
9.2%▼
2023 · 11.6%
Interest coverage
55.09▼
2023 · 59.89
Debt ≤ 1 year
€452,784▼
2023 · €467,817
Debt > 1 year
€226,861▼
2023 · €275,894
Income taxes
€45,088▼
2023 · €49,767
Staff costs
€89,720▼
2023 · €93,509
Green means a favourable move, even when the figure itself falls: as with debt or debt to equity.
Peer companies
Historical observationOf the 34,672 companies that looked in July 2024 the way this one looks now, 0.6% went bankrupt within 24 months and 95% are still going.
- Micro
- 10 to 20 years old
- solvency 30% or more
- a profit of 5% of the balance sheet or more
0.6%
went bankrupt
3.9%
stopped otherwise
95%
still going
A further 0.2% stopped, but we cannot tell whether within those 24 months.
For this company itself Checked computes a bankruptcy probability of 0.8% over twelve months; the group does not contradict it.
How reliable is this rule?
Tested on the year before, without using that year itself: the groups of July 2023 gave each of the 497,058 companies of July 2024 its group's bankruptcy share. Expected: 1.5%; actually bankrupt within 24 months: 1.6%.
| Group | Expected | Actual |
|---|---|---|
| 1 | 0.2% | 0.2% |
| 2 | 0.3% | 0.4% |
| 3 | 0.5% | 0.5% |
| 4 | 0.6% | 0.7% |
| 5 | 0.8% | 0.9% |
| 6 | 1.2% | 1.3% |
| 7 | 1.5% | 1.6% |
| 8 | 1.7% | 1.7% |
| 9 | 2.7% | 2.8% |
| 10 | 5.3% | 5.7% |
The rule ranks well: a company that went bankrupt got a higher share than one that kept going in 74% of comparisons. The level follows the economy: in a year with more bankruptcies, the actual share is higher than the year before.
An observation about 34,672 comparable companies, not a prediction for this company. The sector does not count: the register keeps no sector for companies that stopped, so it would make the outcome look better than it was.
Annual accounts
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | Change |
|---|---|---|---|---|---|---|
| Remuneration, social security and pensions62 | - | €31,065 | €42,603 | €93,509 | €89,720 | ▼ 4.1% |
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630 | €77,950 | €77,901 | €77,981 | €78,179 | €50,184 | ▼ 35.8% |
| Provisions for liabilities and charges: additions (uses and reversals)635/8 | - | €166 | €2,535 | - | - | - |
| Other operating charges640/8 | - | €4,333 | €5,546 | €7,392 | €7,748 | ▲ 4.8% |
| Gross operating margin9900 | €247,021 | €348,402 | €326,494 | €369,448 | €308,603 | ▼ 16.5% |
| Operating profit (loss)9901 | €131,318 | €234,936 | €197,829 | €190,367 | €160,951 | ▼ 15.5% |
| Financial income75/76B | - | €3,028 | €3,151 | €2,657 | €2,383 | ▼ 10.3% |
| Recurring financial income75 | €2,502 | €3,028 | €3,151 | €2,657 | €2,383 | ▼ 10.3% |
| Financial charges65/66B | - | €11,126 | €30,373 | €4,484 | €3,833 | ▼ 14.5% |
| Recurring financial charges65 | €12,379 | €11,126 | €30,373 | €4,484 | €3,833 | ▼ 14.5% |
| Profit (loss) for the period before taxes9903 | €121,441 | €226,838 | €170,607 | €188,540 | €159,502 | ▼ 15.4% |
| Income taxes67/77 | €39,457 | €56,078 | €50,150 | €49,767 | €45,088 | ▼ 9.4% |
| Profit (loss) for the period9904 | €81,984 | €170,760 | €120,457 | €138,773 | €114,414 | ▼ 17.6% |
| Transfer from tax-exempt reserves789 | - | €10,476 | - | - | - | - |
| Profit (loss) for the period to be appropriated9905 | €90,258 | €181,236 | €120,457 | €138,773 | €114,414 | ▼ 17.6% |
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | Change |
|---|---|---|---|---|---|---|
| Assets | ||||||
| Total assets20/58 | €1.4m | €1.4m | €1.2m | €1.2m | €1.2m | ▲ 4.2% |
| Fixed assets21/28 | €951,667 | €883,568 | €816,404 | €739,908 | €700,176 | ▼ 5.4% |
| Intangible fixed assets21 | €84,000 | €58,613 | €30,074 | €1,534 | €995 | ▼ 35.2% |
| Tangible fixed assets22/27 | €866,417 | €823,705 | €785,080 | €738,374 | €699,182 | ▼ 5.3% |
| Land and buildings22 | - | €790,594 | €760,812 | €721,446 | €683,677 | ▼ 5.2% |
| Plant, machinery and equipment23 | - | €5,965 | €4,731 | €4,501 | €5,691 | ▲ 26.4% |
| Furniture and vehicles24 | - | €26,689 | €19,204 | €12,217 | €9,728 | ▼ 20.4% |
| Other tangible fixed assets26 | - | €457 | €333 | €209 | €85 | ▼ 59.2% |
| Financial fixed assets28 | €1,250 | €1,250 | €1,250 | - | - | - |
| Current assets29/58 | €436,701 | €528,853 | €430,882 | €458,388 | €548,468 | ▲ 19.7% |
| Stocks and contracts in progress3 | €140,883 | €136,217 | €145,188 | €176,547 | €207,658 | ▲ 17.6% |
| Stocks30/36 | - | €136,217 | €145,188 | €176,547 | €207,658 | ▲ 17.6% |
| Amounts receivable within one year40/41 | €107,287 | €136,126 | €55,158 | €52,019 | €162,745 | ▲ 213% |
| Trade receivables40 | - | €135,277 | €37,364 | €45,371 | €140,977 | ▲ 211% |
| Other amounts receivable41 | - | €849 | €17,794 | €6,647 | €21,768 | ▲ 227% |
| Cash at bank and in hand54/58 | €115,720 | €233,972 | €131,110 | €119,238 | €174,724 | ▲ 46.5% |
| Deferred charges and accrued income490/1 | - | €22,538 | €99,427 | €110,585 | €3,341 | ▼ 97.0% |
| Equity and liabilities | ||||||
| Total equity and liabilities10/49 | €1.4m | €1.4m | €1.2m | €1.2m | €1.2m | ▲ 4.2% |
| Equity10/15 | €401,713 | €572,473 | €315,813 | €454,586 | €569,000 | ▲ 25.2% |
| Contributions10/11 | - | €18,600 | €18,600 | €18,600 | €18,600 | = |
| Reserves13 | €383,113 | €372,637 | €297,213 | €297,213 | €320,096 | ▲ 7.7% |
| Non-distributable reserves130/1 | - | €1,860 | €1,860 | €1,860 | - | - |
| Reserves not available under the articles1311 | - | €1,860 | €1,860 | €1,860 | - | - |
| Tax-exempt reserves132 | - | €124 | €124 | €124 | €124 | = |
| Distributable reserves133 | - | €370,653 | €295,229 | €295,229 | €319,972 | ▲ 8.4% |
| Profit (loss) carried forward14 | - | €181,236 | - | €138,773 | €230,304 | ▲ 66.0% |
| Amounts payable17/49 | €986,656 | €839,948 | €931,473 | €743,711 | €679,645 | ▼ 8.6% |
| Amounts payable after more than one year17 | €613,691 | €411,832 | €330,158 | €275,894 | €226,861 | ▼ 17.8% |
| Financial debts170/4 | - | €411,832 | €330,158 | €275,894 | €226,861 | ▼ 17.8% |
| Amounts payable within one year42/48 | €367,058 | €422,968 | €601,315 | €467,817 | €452,784 | ▼ 3.2% |
| Current portion of amounts payable after more than one year42 | - | €81,860 | €81,673 | €54,265 | €49,033 | ▼ 9.6% |
| Trade debts44 | €118,441 | €145,601 | €90,576 | €76,617 | €152,589 | ▲ 99.2% |
| Suppliers440/4 | - | €145,601 | €90,576 | €76,617 | €152,589 | ▲ 99.2% |
| Advances received on contracts in progress46 | - | €1,271 | - | €212 | €424 | ▲ 100% |
| Taxes, remuneration and social security45 | - | €53,473 | €51,906 | €42,732 | €23,543 | ▼ 44.9% |
| Taxes450/3 | - | €49,491 | €41,041 | €27,958 | €12,088 | ▼ 56.8% |
| Remuneration and social security454/9 | - | €3,982 | €10,866 | €14,773 | €11,455 | ▼ 22.5% |
| Other amounts payable47/48 | - | €140,764 | €377,159 | €293,992 | €227,195 | ▼ 22.7% |
| Accrued charges and deferred income492/3 | - | €5,149 | - | - | - | - |
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | Change |
|---|---|---|---|---|---|---|
| Profit (loss) for the period9904 | €81,984 | €170,760 | €120,457 | €138,773 | €114,414 | ▼ 17.6% |
| + Depreciation and write-downs630 | €77,950 | €77,901 | €77,981 | €78,179 | €50,184 | ▼ 35.8% |
| Operating cash flow (approximation) | €159,934 | €248,661 | €198,439 | €216,952 | €164,598 | ▼ 24.1% |
| Investment in fixed assets (approximation) | - | -€9,802 | -€10,817 | -€1,684 | -€10,452 | ▼ 521% |
| Change in cash | - | €118,252 | -€102,862 | -€11,872 | €55,486 | ▲ 567% |
Simplified and derived: a Belgian filing has no cash-flow statement, so these rows come from the income statement and the balance-sheet moves.
Timeline · acts, filings and financial milestones
2025
18-07
NBB filing
Annual accounts filed
fiscal year 2024 · abbreviated schema
2024
31-12
Financial
Equity above €500,000Eq €569,000 ▲25.2%
7 profitable years in a row build equity to €569,000.
08-08
NBB filing
Annual accounts filed
fiscal year 2023 · abbreviated schema · 8 days late
2023
22-06
NBB filing
Annual accounts filed
fiscal year 2022 · abbreviated schema
2022
31-08
NBB filing
Annual accounts filed
fiscal year 2021 · abbreviated schema · 31 days late
2021
31-12
Financial
Highest result since 2018net €170,760 ▲108%
Operating result €234,936, net result €170,760, both a record.
31-12
Financial
Equity above €500,000Eq €572,473 ▲42.5%
4 profitable years in a row build equity to €572,473.
26-08
NBB filing
Annual accounts filed
fiscal year 2020 · abbreviated schema · 26 days late
2020
12-10
NBB filing
Annual accounts filed
fiscal year 2019 · abbreviated schema · 73 days late
2019
31-12
Financial
Weakest financial yearnet €64,396 ▼10.5%
Net result drops to €64,396, the lowest in the series; recovery starts the following year.
29-07
NBB filing
Annual accounts filed
fiscal year 2018 · abbreviated schema
2018
23-08
NBB filing
Annual accounts filed
fiscal year 2017 · abbreviated schema · 23 days late
2017
31-07
NBB filing
Annual accounts filed
fiscal year 2016 · abbreviated schema
2016
30-08
NBB filing
Annual accounts filed
fiscal year 2015 · abbreviated schema · 30 days late
Financial milestoneNBB filingFinancial milestones sit on the fiscal year-end date, not the filing date.
0 of 7 acts read
About the unread acts
We know of 7 Belgian State Gazette acts for this company. None of them has been read yet: what they contain is neither established nor disproved here.
Have them read with priority
Sign in to place this company at the front of the reading queue.
Directors · office · real estate
Directors
7 acts for this company are in the Belgian State Gazette, of which we have read 0. We have therefore not extracted its directors from those acts yet.
Location & real-estate footprint
Registered office, Roeselare · 1 establishment unit since 2014
Ground area
3,426 m²
Building footprint
711 m²
Volume, LiDAR
2,100 m³
2 parcels, Flanders · tallest building 10.1 m, ±2 floors. Linked by address, not a title deed.
1 establishment unit
Apotheek Princen
since 20142.226.556.806
2 parcels
Flanders
2
(100%)
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 36302B0645/00D000 | Flanders | 1,926 m² | 1 · 287 m² | 10.1 m · 2 fl. |
| 36302B2103/00D000 | Flanders | 1,500 m² | 1 · 424 m² | 6.6 m |
Linked by address, not proof of ownership
Good to know
2 of 2 parcels with an exact address match; the rest are indicative.
Linked through address data, this is not proof of ownership.
Structure & network
Owners and holdings
1 ownerChain of control
- JM
- Alpha pharma
Highest known parent: JM. The sources do not say who stands above it.
Owners 1
- JMparentSourceaccounts JM 202480%
Holdings 0
No holding stated in the accounts, acts or LEI register we read.
According to the annual accounts of the other companies, the acts in the Belgian Gazette and the LEI register. The register of ultimate beneficial owners (UBO) is not public: who ultimately stands behind a natural person or a foreign parent is not stated here. A company that does not fill in these statements, or need not, is missing.
Connections & network
No current directors or connected companies found in the register.
Similar companies · same sector, comparable size
PHARMACIE GHISBAIN
BE 0885.860.517
Seraing · Eq €568,876
Apotheek N. Debaere
BE 0430.148.577
Wevelgem · Eq €569,913
LESAGE - VANDEVELDE
BE 0424.682.133
Oudenburg · Eq €567,730
APOTHEEK STICKER
BE 0441.007.926
Ieper · Eq €571,131
APOTHEEK BUFAR
BE 0429.561.035
Zoutleeuw · Eq €571,190
Of 5,220 companies in sector 47730 we hold annual accounts for 3,860. 3,307 are within a factor 10 of this equity. The 5 above are the closest to it. See the whole sector
Identification & contact
Identification
Legal formPrivate limited company
Founded17-01-2014
Fiscal year end31-12
Activities, NACEBEL 2025
47730Retail sale of pharmaceutical products
E-invoicing
Reachable via Peppol
Peppol ID
0208:0544737350
Registered
03-05-2025
Register as of 26 September 2026 · Peppol Directory
Scores and ratios are computed by Checked and are not a credit decision.